The Organizing Committee is delighted to invite you to attend the 12th European Biosimilars Congress one of its remarkable Pharmaceutical conferences, to be held during April 15-16, 2019 in Berlin, Germany. European Biosimilars Congress is a global annual event. This European Biosimilars Congress 2019 will bring together scientists, researchers, business development managers, CEOs, directors, IP Attorneys, Regulatory Officials and CROs from around the world. Many biologics products are making their entry in the pharma market and experiencing a notable rise in their usage over the conventional medications.
• Current Challenges in Developing Biosimilars
• Analytical Strategies for Biosimilars
• Intellectual Property Rights
• Biological Medicine
• Emerging Biosimilars in Therapeutics
• Innovative Clinical Approach in Biosimilars
• Regulatory Updates on Biosimilars
• Biosimilars Development in Markets
• Biosimilars Approval to Biogenerics in Clinical Practice
• Biopharmaceutical Informatics
• Consequences of Brexit on Biosimilars
• BCS and IVIVC Based Biowaivers
• Biosimilars Market and Cost Analysis
• Challenges in Biosimilars Pharmacovigilance
• Legal Issues and BPCI Act
• Formulation Strategies for Follow-on Biologics
• Current Agency Expectations for Approval for Biosimilars
• Biosimilars Research Pipeline
• Globalization of Biosimilars
• Drug Delivery and Development
• Monoclonal Antibody Biosimilars
• USFDA Approved Biosimilars
Happily invite attendees from Chief Executives, Directors, Vice Presidents, Department Heads, Leaders and Managers specialising in:
Biologics/Biotechnology/ Biogenerics, Legal Affairs, Pricing and Reimbursement, Regulatory Compliance, Preclinical and Clinical Development, Quality Affairs/ Quality Control, Biopharmaceuticals, Intellectual property, Clinical Immunology, R&D, New Product Development and Pharmacovigilance
From Industries Including:
Clinical Immunology, Immunology, Drug Safety, Preclinical Development, Therapeutic Areas, Business Development, Vaccines Development, Scientific Affairs, Validation, Analytical Characterization, Antibody Discovery, Oncology, Infection and Immunity, Risk Management, Clinical Program, Personalized Medicine, Portfolio Planning, Regulatory Affairs, Pharmacovigilance, Global Strategy and Antibody Engineering
If this page is in your subscriptions, then it will be removed. You will not see this page. If you want to unblock a user, go to the settings, the list of blocked users and click unblock